QRX Share Price

Open 0.02 Change Price %
High 0.03 1 Day 0.00 0.00
Low 0.02 1 Week 0.00 0.00
Close 0.03 1 Month 0.00 0.00
Volume 3675565 1 Year 0.00 0.00
52 Week High 0.14
52 Week Low 0.00
QRX Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.03
Support 1 0.02
Support 2 0.02
ASX Australia Most Active Stocks
LKO 0.00 0.00%
RRS 0.00 0.00%
RRS 0.00 0.00%
RRS 0.00 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
MGZ 0.02 100.00%
AOK 0.02 100.00%
AAJ 0.02 100.00%
TAG 0.08 60.00%
BNV 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
NSL 0.03 50.00%
More..
ASX Australia Top Losers Stocks
FUN 0.00 -100.00%
FUN 0.00 -100.00%
FUN 0.00 -100.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
AKF 0.03 -50.00%
GPP 0.01 -50.00%
More..

QRxPharma Ltd (ASX: QRX)

QRX Technical Analysis 2
As on 22nd May 2015 QRX Share Price closed @ 0.03 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.04 & Strong Buy for SHORT-TERM with Stoploss of 0.02 we also expect STOCK to react on Following IMPORTANT LEVELS.
QRX Target for October
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
QRX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.qrxpharma.com
QRX Address
QRX
100 Walker Street
Level 11
North Sydney, NSW 2060
Australia
Phone: 61 2 9492 8021
Fax: 61 2 8920 0314
QRX Latest News
Interactive Technical Analysis Chart QRxPharma Ltd ( QRX ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on QRxPharma Ltd
QRX Business Profile
QRxPharma Limited, a specialty pharmaceutical company, develops and commercializes biopharmaceutical products primarily in Australia. The company’s pain management products include MOXDUO, which is an immediate-release oral capsule for the treatment of moderate to severe acute pain; Q8011, a controlled-release oral tablet that is a proprietary morphine/oxycodone formulation in Phase II clinical trials to provide analgesia in patients suffering from moderate to severe chronic pain; and Q8012, an intravenous dual opioid formulation of morphine and oxycodone, which has completed Phase II trial for acute moderate to severe hospital-based pain. It has a collaboration agreement with Aesica Formulation Development Limited for the promotion of its proprietary Stealth Beadlets abuse deterrence technology. QRxPharma Limited is based in North Sydney, Australia.